- Recommendation ID
- NG97/3
- Question
Anticholinergic burden:- Does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual care?
- Any explanatory notes
(if applicable) Why this is important:- Many people living with dementia are still prescribed medicines with a high anticholinergic burden (which can be caused by individual medicines or by combinations of medicines). It is often unclear if this prescribing is appropriate, or whether actively reducing the number of these medicines would improve cognition. Randomised controlled trials could be conducted, using structured tools to assess anticholinergic burden and actively switching medicines if possible. This would help to
identify whether cognition can be improved without adversely affecting the management of the conditions these medicines are prescribed for.
Source guidance details
- Comes from guidance
- Dementia: assessment, management and support for people living with dementia and their carers
- Number
- NG97
- Date issued
- June 2018
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 30/06/2018 |